Stay updated on Pyrotinib Plus Vinorelbine in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib Plus Vinorelbine in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the Pyrotinib Plus Vinorelbine in HER2+ Breast Cancer Clinical Trial page
- Check2 days agoChange DetectedA new revision entry (v3.6.0) was added to the study history, introducing the verifier’s name (wang shusen) and updated last-verified metadata. The change strengthens the audit trail by clarifying who verified the record and which version is current.SummaryDifference3%

- Check9 days agoChange DetectedThe study record's revision history now includes a new entry for v3.5.5 and removes the previous v3.5.4 entry, updating the version history to reflect the latest submission.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision tag in the page footer updated from v3.5.3 to v3.5.4, indicating a minor site version update rather than changes to the study record.SummaryDifference0.1%

- Check45 days agoChange DetectedLatest revision in the Study Record History is now Revision: v3.5.3, replacing Revision: v3.5.2. This update records a new metadata version for the record rather than altering substantive study details.SummaryDifference0.1%

- Check59 days agoChange DetectedA new UI revision entry, v3.5.2, was added to the Record History and an older revision, v3.5.0, was removed.SummaryDifference0.1%

- Check88 days agoChange DetectedRevision v3.5.0 was added and revision v3.4.3 was removed from the Record History.SummaryDifference0.1%

Stay in the know with updates to Pyrotinib Plus Vinorelbine in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib Plus Vinorelbine in HER2+ Breast Cancer Clinical Trial page.